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Several lines of evidence suggest that genome-wide association studies (GWASs) have the potential to explain more of the ‘‘missing heri-
tability’’ of common complex phenotypes. However, reliable methods for identifying a larger proportion of SNPs are currently lacking.
Here, we present a genetic-pleiotropy-informedmethod for improving gene discovery with the use of GWAS summary-statistics data.We
applied this methodology to identify additional loci associated with schizophrenia (SCZ), a highly heritable disorder with significant
missing heritability. Epidemiological and clinical studies suggest comorbidity between SCZ and cardiovascular-disease (CVD) risk factors,
including systolic blood pressure, triglycerides, low- and high-density lipoprotein, body mass index, waist-to-hip ratio, and type 2 dia-
betes. Using stratified quantile-quantile plots, we show enrichment of SNPs associated with SCZ as a function of the association with
several CVD risk factors and a corresponding reduction in false discovery rate (FDR). We validate this ‘‘pleiotropic enrichment’’ by
demonstrating increased replication rate across independent SCZ substudies. Applying the stratified FDR method, we identified 25
loci associated with SCZ at a conditional FDR level of 0.01. Of these, ten loci are associated with both SCZ and CVD risk factors, mainly
triglycerides and low- and high-density lipoproteins but also waist-to-hip ratio, systolic blood pressure, and body mass index. Together,
these findings suggest the feasibility of using genetic-pleiotropy-informedmethods for improving gene discovery in SCZ and identifying
potential mechanistic relationships with various CVD risk factors.Introduction
Complex human traits and disorders are influenced by
numerous genes that each have small individual effects,1
and thousands of SNPs have been identified by genome-
wide association studies (GWASs).2,3 However, these SNPs
fail to explain a substantial proportion of the heritability
of the complex phenotypes studied;4 this is often referred
to as the ‘‘missing heritability.’’ Recent results indicate that
GWASs have the potential to explain a greater proportion
of the heritability of common complex phenotypes,5,6
and additional SNPs are likely to be identified in larger
samples.7 Because of the polygenic architecture of most
complex traits and disorders, a large number of SNPs
have associations too weak to be identified in the currently
available sample sizes.4 Cost-effective analytical methods
are needed for reliably identifying a larger proportion of
SNPs associated with complex diseases and phenotypes
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The Americis expensive. Here, we present a genetic-pleiotropy-
informed approach for GWASs to capture more of the
polygenic effects in complex disorders and traits. Given
the high number of traits in humans and the relative small
number of genes (~20,000), some genes have to affect
multiple traits (genetic pleiotropy).8 By combining inde-
pendent GWASs from associated traits or comorbid disor-
ders, we hypothesize that a genetic-pleiotropy-informed
approach can significantly improve discovery of genes
and help capture a greater proportion of the missing
heritability.
Reports indicate overlapping SNPs between several
human traits9,10 and disorders.11,12 To date, methods for
assessing genetic pleiotropy have not taken full advantage
of the existing GWAS data, and the majority of these
studies have focused on the subset of SNPs exceeding
a Bonferroni-corrected threshold of significance for each
trait or disorder.10,13 However, this approach cannot
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combined analysis (hereafter referred to as polygenic plei-
otropy) but do not meet Bonferroni-corrected significance
in the individual phenotype. Combining GWASs from two
traits or disorders also provides increased power to discover
genes associated with common biological mechanisms
and to potentially inform shared pathophysiological rela-
tionships between the phenotypes. In the current study,
we use schizophrenia (SCZ [MIM 181500]) as an example
of how a pleiotropy-informed analytical approach can
improve gene discovery in a disorder with high herita-
bility14 and for which, despite recent discoveries,13,15,16
most of the underlying genetic architecture remains
unknown.13
SCZ, a debilitating mental health disorder, is among
the leading global causes of disability17 and constitutes a
substantial portion of disease burden worldwide. System-
atic reviews and meta-analyses indicate that individuals
with SCZ have significantly higher mortality rates than
the general population, and this corresponds to a 10–20
year reduction in life expectancy.18–20 Although the
mortality rate from suicide is high, lifestyle and cardiovas-
cular-disease (CVD) risk factors contribute substantially to
life-expectancy reduction in SCZ.19–21 Epidemiological
research has shown increased rates of dyslipidemia, type
2 diabetes (T2D [MIM 125853]), and obesity (MIM
601665) and a high prevalence of metabolic syndrome
among people with SCZ.22 This increase in CVD risk
factors has been primarily attributed to lifestyle factors
such as unhealthy diet, sedentary habits, excessive
smoking, and the side effects of antipsychotic medica-
tion.19,23–25 However, as suggested by studies predating
the introduction of antipsychotics,26 studies of untreated
first-episode individuals and their healthy relatives,27 and
the identification of overlapping candidate genes,28 shared
genetics between SCZ and CVD risk factorsmight also be of
importance.
Large GWASs have reported SNPs associated with a
number of CVD risk factors, including systolic blood pres-
sure (SBP), diastolic blood pressure (DBP),29 low-density
lipoprotein (LDL) cholesterol,30 high-density lipoprotein
(HDL) cholesterol,30 triglycerides (TGs),30 T2D,31 body
mass index (BMI),32 and waist-to-hip ratio (WHR).33 In
the current study, we employed model-free strategies and
leveraged the power of multiple large independent GWASs
to identify SNPs exhibiting pleiotropy between SCZ and
eight CVD risk factors by using summary statistics from
six studies. After applying genomic inflation control, we
computed the stratified empirical cumulative distribution
functions (cdfs) of the nominal p values. Strata were deter-
mined by the relative enrichment of pleiotropic SNPs in
SCZ as a function of increased nominal p values in the
different CVD risk factors. For each nominal p value,
an estimate of the stratum-specific true discovery rate
(TDR ¼ 1 – false discovery rate [FDR]) was obtained from
the empirical cdfs.34,35 We demonstrate that the stratified
analysis improves power to detect SNPs by computing
replication rates for nominal p value thresholds by using198 The American Journal of Human Genetics 92, 197–209, Februaryindependent substudies for discovery and replication
samples. We show that for a given replication rate,
nominal p value thresholds are approximately 100 times
larger for the most pleiotropic SNPs in SCZ than for all
SNPs (hereafter referred to as genetic enrichment). Using
this stratified methodology, we constructed a two-dimen-
sional (2D) FDR ‘‘look-up’’ table in which the FDR in SCZ
SNPs was computed conditionally on nominal CVD-risk-
factor p values (this is referred to as conditional FDR). Using
this table, we identified 25 loci that are significantly associ-
ated with SCZ at a conditional FDR level of 0.01. Finally, we
constructed the conjunction FDR to investigate SNPs signif-
icantly associated with both SCZ and CVD risk factors.
Specifically, we computed the conditional FDR for SCZ
given CVD-risk-factor nominal p values, as well as con-
ditional FDR for CVD risk factors given SCZ nominal
p values, and we took the maximum of both values as
the conjunction FDR. With this approach, we identified
ten pleiotropic loci implicating overlapping genetic mech-
anisms between SCZ and blood lipids.Material and Methods
Participant Samples
We obtained complete GWAS results in the form of summary-
statistics p values from public-access websites or through collabo-
ration with investigators (T2D cases and controls were from the
Diabetes Genetics Replication and Meta-analysis [DIAGRAM]
Consortium, and SCZ cases and controls were from the Psychiatric
GWAS Consortium [PGC] [Table S1, available online]). There was
no overlap between participants in the CVD GWAS and the SCZ
case-control sample (n ¼ 21,856), except for 2,974 of 12,462
(24%) controls.13
The SCZ GWAS summary-statistics results were obtained from
the PGC,13 which consists of 9,394 cases with SCZ or schizoaffec-
tive disorder and 12,462 controls (52% screened) from a total of
17 samples from 11 countries. The quality of phenotypic data
was verified by a systematic review of data-collection methods
and procedures at each site, and only studies that fulfilled these
criteria were included. This involved the following nine key items:
(1) the use of a structured psychiatric interview, (2) systematic
training of interviewers in the use of the instrument, (3) system-
atic quality control of diagnostic accuracy, (4) reliability trials,
(5) review of medical-record information, (6) best-estimate proce-
dure employed, (7) specific inclusion and exclusion criteria devel-
oped and utilized, (8) final diagnostic determination made by
MDs or PhDs, and (9) special additional training for the final
SCZ PGC sample. One sample from Sweden used another
approach, but further empirical support for the validity of this
approach was provided. Controls consisted of 12,462 European-
ancestry samples collected from the same countries. Because the
prevalence of SCZ is low, a large control sample in which some
controls were not screened for SCZ was utilized. For further details
on sample characteristics and quality-control procedures applied,
please see Ripke et al.13 A total of 2,974 controls in the SCZ UK
case-control sample16 from the Wellcome Trust Case Control
Consortium (WTCCC) were also included in several of the CVD-
risk-factor GWASs. This constitutes 24% of the total number of
controls (n ¼ 12,462) in the SCZ PGC sample.137, 2013
More information about inclusion criteria and phenotype char-
acteristics of the CVD-risk-factor samples of the different GWASs is
included in the original publications.29–33 The relevant institu-
tional review boards or ethics committees approved the research
protocol of the individual GWASs used in the current analysis,
and all human participants gave written informed consent.Statistical Analyses
Stratified Quantile-Quantile Plots
Quantile-quantile (Q-Q) plots compare a nominal probability
distribution against an empirical distribution. In the presence of
all null relationships, nominal p values form a straight line on
a Q-Q plot when they are plotted against the empirical distribu-
tion. For each phenotype, for all SNPs, and for each categorical
subset (strata), log10 nominal p values were plotted against
log10 empirical p values (stratified Q-Q plots). Leftward deflec-
tions of the observed distribution from the projected null line
reflect increased tail probabilities in the distribution of test statis-
tics (Z scores) and, consequently, an overabundance (also termed
‘‘enrichment’’) of low p values compared to that expected by
chance.
Under large-scale testing paradigms, such as GWASs, quantita-
tive estimates of probably true associations can be estimated
from the distributions of summary statistics.36,37 A common
method for visualizing the enrichment of statistical association
relative to that expected under the global null hypothesis is
through Q-Q plots of nominal p values obtained from GWAS
summary statistics. The usual Q-Q curve has the nominal p value,
denoted by ‘‘p,’’ as the y ordinate and the corresponding value of
the empirical cdf, denoted by ‘‘q,’’ as the x ordinate. Under the
global null hypothesis, the theoretical distribution is uniform on
the interval [0, 1]. As is common in GWASs, we instead plot
log10(p) against log10(q) to emphasize tail probabilities of the
theoretical and empirical distributions. Therefore, genetic enrich-
ment results in a leftward shift in the Q-Q curve, corresponding to
a larger fraction of SNPs with a nominal log10 p value greater
than or equal to a given threshold. Stratified Q-Q plots are con-
structed by the creation of subsets of SNPs on the basis of levels
of an auxiliary measure for each SNP and the computation of
Q-Q plots separately for each level. If SNP enrichment is captured
by variation in the auxiliary measure, this is expressed as succes-
sive leftward deflections in a stratified Q-Q plot as levels of the
auxiliary measure increase.
Genomic Control
The empirical null distribution in GWASs is affected by global vari-
ance inflation due to population stratification and cryptic related-
ness38 and deflation due to overcorrection of test statistics for
polygenic traits by standard genomic-control methods,39 in addi-
tion to incorrect asymptotic approximation used for computing
the p values. We applied a control method leveraging only inter-
genic SNPs, which are most likely depleted for true associations
(unpublished data). First, we annotated the SNPs to genic
(50 UTR, exon, intron, and 30 UTR) and intergenic regions by using
information from the 1000Genomes Project (1KGP). As illustrated
in Figure S1, there are more functional genic regions than inter-
genic regions in SCZ. We used intergenic SNPs because their rela-
tive depletion of associations suggests that they provide a robust
estimate of true null effects, and they thus seem to be a better cate-
gory for genomic control than all SNPs. We converted all p values
to Z scores, and for each phenotype, we estimated the genomic
inflation factor lGC for intergenic SNPs. We computed the infla-The Americtion factor lGC as the median Z score squared divided by the ex-
pected median of a chi-square distribution with one degree of
freedom, and we adjusted all test statistics by lGC. The stratified
Q-Q plot for SCZ after control for genomic inflation is shown in
Figure S1.
Stratified Q-Q Plots for Pleiotropic Enrichment
To assess pleiotropic enrichment, we used a Q-Q plot stratified by
‘‘pleiotropic’’ effects. For a given associated phenotype, enrich-
ment for pleiotropic signals is present if the degree of deflection
from the expected null line is dependent on SNP associations
with the second phenotype. We constructed stratified Q-Q plots
of empirical quantiles of nominal –log10(p) values for SNP associ-
ation with SCZ for all SNPs, as well as for subsets (strata) of SNPs
determined by the nominal p values of their association with
a given CVD risk factor. Specifically, we computed the empirical
cumulative distribution of nominal p values for a given phenotype
for all SNPs and for SNPs with significance levels below the
indicated cutoffs for the other phenotype (–log10(p) R 0,
–log10(p) R 1, –log10(p) R 2, and –log10(p) R 3 corresponding
to p < 1, p < 0.1, p < 0.01, and p < 0.001, respectively). The
nominal p values (–log10(p)) are plotted on the y axis, and
the empirical quantiles (–log10(q), where q ¼ cdf(p)) are plotted
on the x axis. To assess polygenic effects below the standard
GWAS significance threshold, we focused the stratified Q-Q
plots on SNPs with nominal –log10(p) < 7.3 (corresponding to
p > 5 3 108).
Significance of Enrichment
Using Q-Q plots (with 95% confidence intervals [CIs]) of empirical
versus nominal –log10(p) values in SCZ as a function of the signif-
icance of association with the CVD risk factors, we estimated the
significance of the polygenic enrichment (Figures S2A–S2C). After
using intergenic SNPs to estimate and control for genomic infla-
tion (Figure S1), we pruned the SNPs by removing SNPs in linkage
disequilibrium (LD) (r2R 0.2) and computed 95% CIs for the Q-Q
plots. From these CIs, we calculated standard errors and used two
sample t tests to estimate the difference (degree of departure)
between the empirical distribution of SCZ (phenotype 1) SNPs
that were above a given association threshold (–log10(p) > 1,
–log10(p) > 2, –log10(p) > 3, and –log10(p) > 4; red lines) and
the distribution of SNPs with –log10(p) % 1 for the CVD-risk-
factor (phenotype 2) category (blue line). The p values listed in
Table S5 indicate the most significant difference, as assessed by
a two-sample t test, between the red (–log10(p) > 1, 2, 3, or 4)
and blue (–log10(p)% 1) lines. This is reflected in the largest differ-
ence between the 95% CIs. The 95% CIs also illustrate the region
containing significant differences in the Q-Q plot. For differences
between the distributions, we only report p values appearing
above the –log10(p) > 2 threshold on the Q-Q plots. This clearly
shows significant enrichment conditioning SCZ on TG and WHR.
For the CVD risk factors with significant enrichment, we further
calculated the significance of the enrichment for SNPs with a
Fisher’s combined p value below the genome-wide significance
level of 5 3 108, and we hereafter refer to this as ‘‘censoring.’’
This made it possible to examine whether the enrichment was
entirely explained by the most significant pleiotropic SNPs or
whether it was due to a more general, polygenic effect (polygenic
pleiotropy). As illustrated for SCZ and TG in Figure S2C, the poly-
genicpleiotropic enrichment ishighly significant. See alsoTable S5.
Stratified TDR
Enrichment seen in the stratified Q-Q plots can be directly
interpreted in terms of TDR (equivalent to 1  FDR40). We
applied the stratified FDR method,35 previously used for GWASan Journal of Human Genetics 92, 197–209, February 7, 2013 199
enrichment based on linkage information.34 Specifically, for
a given p value cutoff, the FDR is defined as
FDRðpÞ ¼ p0F0ðpÞ
FðpÞ ; (Equation 1)
where p0 is the proportion of null SNPs, F0 is the null cdf, and F is
the cdf of all SNPs, both null and non-null; see below for details on
this simple mixture-model formulation.41 Under the null hypoth-
esis, F0 is the cdf of the uniform distribution on the unit interval
[0, 1], so Equation 1 reduces to
FDRðpÞ ¼ p0p
FðpÞ : (Equation 2)
The cdf F can be estimated by the empirical cdf q¼Np / N, where
Np is the number of SNPs with a p value less than or equal to
p and N is the total number of SNPs. By replacing F with q in
Equation 2, we get
Estimated FDRðpÞ ¼ p0p
q
; (Equation 3)
which is biased upward as an estimate of the FDR.41 Replacing p0
in Equation 3 with unity gives an estimated FDR that is further
biased upward:
q ¼ p
q
: (Equation 4)
If p0 is close to 1, as is probably true for most GWASs,
the increase in bias from Equation 3 is minimal. The quantity
1 – p / q is therefore biased downward and hence is a conservative
estimate of the TDR.
Referring to the formulation of the Q-Q plots, we see that q* is
equivalent to the nominal p value divided by the empirical quan-
tile, as defined earlier. Given the –log10 of the Q-Q plots, we can
easily obtain
log10ðqÞ ¼ log10ðqÞ  log10ðpÞ; (Equation 5)
demonstrating that the (conservatively) estimated FDR is directly
related to the horizontal shift of the curves in the stratified Q-Q
plots from the expected line x ¼ y, i.e., a larger shift corresponds
to a smaller FDR, as illustrated in Figure 1. As before, the estimated
TDR can be obtained as 1  FDR. For each range of p values
(stratum) in a pleiotropic trait, we calculated the TDR as a function
of p values in SCZ (indicated by different colored curves) in
Figure 1 by using each observed p value as a threshold according
to Equation 5.
Estimates of Pleiotropy
Let z be the GWAS test statistic for a corresponding p value. The
two-group mixture model for Z scores implicit in Equation 1 is
given by
fðzÞ ¼ p0f0ðzÞ þ ð1 p0Þf1ðzÞ; (Equation 6)
where f0 is the null distribution (standard normal after appropriate
genomic control), f1 is the non-null distribution (which can be
estimated parametrically or nonparametrically),36 and p0 is the
proportion null, as before. We can easily generalize this model to
two Z scores from phenotypes simultaneously (z1 for phenotype
1 and z2 for phenotype 2) by using a bivariate density from the
four-group mixture model,
fðz1; z2Þ ¼ p0f0ðz1; z2Þ þ p1f1ðz1; z2Þ þ p2f2ðz1; z2Þ þ p3f3ðz1; z2Þ;
(Equation 7)200 The American Journal of Human Genetics 92, 197–209, Februarywhere p0 is the proportion of SNPs for which both phenotypes are
null, p1 is the proportion of SNPs for which phenotype 1 is non-
null and phenotype 2 is null, p2 is the proportion of SNPs for
which phenotype 1 is null and phenotype 2 is non-null, and p3
is the proportion of SNPs for which both phenotypes are non-
null (i.e., the pleiotropic SNPs). The mixture densities in Equation
7 are given by
f0ðz1; z2Þ ¼ 4ðz1Þ 4ðz2Þ
f1ðz1; z2Þ ¼ g1ðz1Þ 4ðz2Þ
f2ðz1; z2Þ ¼ 4ðz1Þ g2ðz2Þ
f3ðz1; z2Þ ¼ g1ðz1Þ g2ðz2Þ;
(Equation 8)
where f() denotes the standard normal density and g1 and g2
denote the non-null marginal densities of z1 and z2, respectively.
We found that modeling the marginal non-null densities with
normal Laplace densities or the Weibull distribution on the
squared Z scores (z2) (in which case the null densities are central
chi-square with one degree of freedom) fits the data well. The
proportions p ¼ (p0,p1,p2,p3) and the parameters of the non-
null distributions can be estimated with maximum likelihood
or Bayesian methods such as Markov Chain Monte Carlo. From
the probability density function (pdf) (Equation 7), we can
compute the joint and conditional cdfs, and hence the FDR
(Equation 2), of one phenotype conditionally on tail probabilities
of the second.
Figure S3 presents the observed and fitted Q-Q curves for SCZ,
TG, and WHR; these curves are based on the marginal cdfs from
the bivariate-mixture-model fits, indicating very good fit. The
non-null distributions were modeled parametrically with Weibull
distributions for non-null z2 and with chi-square with one degree
of freedom for null z.2 The estimated vector of probabilities p from
these fits can also be used for testing whether the degree of pleiot-
ropy is significantly higher than that expected by chance if both
phenotypes are independent. Independence implies that the joint
pdf of both phenotype Z scores is a product of two two-group
mixtures (Equation 6). It is easy to show that demonstrating excess
pleiotropy from that predicted by independence is equivalent to
showing that p3 > p1p2 / p0 in Equation 7 or that the log odds
ratio (LOR)
LORðphenotype 1;phenotype 2Þ ¼ log

p3
1 p3

 log
 ðp1p2=p0Þ
ð1 p1p2=p0Þ

(Equation 9)
is greater than zero. With a multivariate normal approximation
to the maximum-likelihood estimates with covariance obtained
from the inverse Fisher information matrix, estimates of LOR
with 95% CIs are LOR(SCZ,TG) ¼ 4.0 [3.8, 4.3] and
LOR(SCZ,WHR) ¼ 2.4 [2.1, 2.7], which are both highly signifi-
cantly different from zero. These 95% CIs include an adjustment
that assumes an effective degree of freedom of 500,000 indepen-
dent SNPs to account for the correlation of SNPs (i.e., LD).
Stratified Replication Rate
For each of the 17 substudies contributing to the final meta-anal-
ysis in SCZ, we independently adjusted Z scores by using inter-
genic inflation control. For 1,000 of the possible combinations
of the eight-study discovery sets and nine-study replication sets,
we calculated the eight-study combined discovery Z score and
eight- or nine-study combined replication Z score for each SNP
as the average Z score across the eight or nine studies and
multiplied these by the square root of the number of studies.7, 2013
Figure 1. Enrichment and Replication
(A and B) Stratified Q-Q plot of nominal versus empirical –log10 p values (corrected for inflation) in SCZ below the standard GWAS
threshold of p < 5 3 108 as a function of significance of association with (A) TGs and (B) WHR at the levels of –log10(p) > 0,
–log10(p) > 1, –log10(p) > 2, and –log10(p) > 3, which correspond to p < 1, p < 0.1, p < 0.01, and p < 0.001, respectively. Dashed lines
indicate the null hypothesis.
(C and D) Stratified TDR plots illustrating the TDR increase associated with increased pleiotropic enrichment in (C) SCZ conditioned on
TG (SCZjTG) and (D) SCZ conditioned on WHR (SCZjWHR).
(E and F) Cumulative replication plot showing the average rate of replication (p < 0.05) within SCZ substudies for a given p value
threshold demonstrates that pleiotropic enriched SNP categories replicate at a higher rate in independent SCZ samples for (E) SCZ condi-
tioned on TG (SCZjTG) and (F) SCZ conditioned on WHR (SCZjWHR). The vertical intercept is the overall replication rate per category.
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For discovery samples, the Z scores were converted to two-tailed p
values, whereas replication samples were converted to one-tailed p
values, preserving the direction of effect in the discovery sample.
For each of the 1,000 discovery-replication pairs, cumulative rates
of replication were calculated over 1,000 equally spaced bins
spanning the range of negative log10(p values) observed in the
discovery samples. The cumulative replication rate for any bin
was calculated as the proportion of SNPs with a –log10(discovery
p value) greater than the lower bound of the bin with a replication
p value < 0.05. Cumulative replication rates were calculated
independently for each of the four pleiotropic enrichment
categories, as well as for intergenic SNPs and all SNPs. For each
category, the cumulative replication rate for each bin was
averaged across the 1,000 discovery-replication pairs, and the
results are reported in Figure 1. The vertical intercept is the overall
replication rate.
Stratified Replication Effect Sizes
Stratified TDR is directly related to stratified replication effect sizes
and hence replication rates.
As before, for each of the 17 substudies contributing to the
final meta-analysis in SCZ, we independently adjusted Z scores
by using intergenic inflation control. For 1,000 of the possible
combinations of the eight-study discovery sets and nine-study
replication sets, we calculated the eight-study combined discovery
Z score and eight- or nine-study combined replication Z score
for each SNP. The effect sizes were stratified by levels of
log10(p values) from the TG GWAS. As illustrated in Figure S4,
we also calculated the cumulative replication rate without over-
lapping controls (we removed the UK sample that included the
WTCCC controls).
For visualization, a cubic smoothing spline was fit for relating
the discovery Z score bin midpoints to the corresponding average
replication Z scores (see Figure S5). The nonlinear pattern of
shrinkage is typical of that observed inmixturemodels, as in Equa-
tion 1. Importantly, the amount of shrinkage is highly dependent
on enrichment stratum: replication effect sizes in more enriched
strata exhibit more fidelity with discovery sample effect sizes.
This directly relates to increased TDR and translates into increased
replication rates for enriched strata.
Conditional Statistics—Test of Association with SCZ
To improve detection of SNPs associated with SCZ, we used a strat-
ified FDR approach in which we leveraged associated phenotypes
by using established stratified FDR methods.34,35 Specifically, we
stratified SNPs on the basis of p values in the pleiotropic pheno-
type (e.g., TGs). On the basis of the combination of p values for
the SNP in SCZ and the pleiotropic trait, we then assigned a condi-
tional FDR value (denoted as FDRSCZ j TG) for SCZ to each SNP by
interpolating into a 2D look-up table (Figure S6). All SNPs with
FDR < 0.01 (–log10(FDR) > 2) in SCZ given the different CVD
risk factors are listed in Table 1 after ‘‘pruning’’ (removing all
SNPs with r2 > 0.2 according to 1KGP LD structure). A significance
threshold of FDR < 0.01 corresponds to 1 false positive per 100
reported associations. We also list all SNPs with FDR < 0.05
(–log10(FDR) > 1.3) in Table S2.
Conditional Manhattan Plots
To illustrate the localization of the genetic markers associated with
SCZ given the CVD-risk-factor effect, we created a ‘‘conditional
Manhattan plot’’ by plotting all SNPs within an LD block in rela-
tion to their chromosomal location. As illustrated in Figure 2,
the large points represent the SNPs with FDR < 0.05, whereas
the small points represent the nonsignificant SNPs. All SNPs
without pruning are shown. The strongest signal in each LD block202 The American Journal of Human Genetics 92, 197–209, Februaryis illustrated with a black line around the circles. We identified
these signals by ranking all SNPs in increasing order on the basis
of the conditional FDR value for SCZ and then by removing
SNPs in LD r2> 0.2 with any higher ranked SNP. Thus, the selected
locus was the most significantly associated with SCZ in each LD
block (Figure 2).
Conjunction Statistics—Test of Association with Both Phenotypes
In order to identify which of the SNPs associated with SCZ given
the CVD risk factor (SCZjCVD, Table 1) were also associated with
CVD risk factors given SCZ (opposite direction), we calculated
the conditional FDR in the other direction (CVDjSCZ). This is
reported in Table 2. The corresponding Z scores are listed in
Table S3. The Z scores were calculated from the p values, and the
direction of effect was determined by the risk allele.
In addition, to make a comprehensive, unselected map of pleio-
tropic signals, we used a conjunction testing procedure, as out-
lined for p value statistics in Nichols et al.,42 and adapted this
method for FDR statistics on the basis of the conditional-FDR
approach.34,35 On the basis of the combination of p values for
the SNP in SCZ and the pleiotropic trait, we defined the conjunc-
tion statistics (denoted as FDRSCZ & TG) as the maximum condi-
tional FDR in both directions, i.e.,
FDRSCZ & TG ¼ max

FDRSCZ jTG; FDRTG j SCZ

;
by interpolating into a bidirectional 2D look-up table (Figure S7).
The conjunction statistic allows for identification of SNPs that are
associated with both phenotypes, which minimizes the effect of
a single phenotype driving the common association signal. All
SNPs with conjunction FDR < 0.05 (–log10(FDR) > 1.3) with SCZ
and any of the CVD risk factors considered are listed in Table S4
(after pruning).
Conjunction Manhattan Plots
To illustrate the localization of the pleiotropic genetic markers
in association with both SCZ and CVD risk factors, we used a
conjunction Manhattan plot, for which we plotted all SNPs
with a significant conjunction FDR within an LD block in relation
to their chromosomal location. As illustrated in Figure S8, the
large points represent the significant SNPs (FDR < 0.05), whereas
the small points represent the nonsignificant SNPs. All SNPs
without pruning are shown, and the strongest signal in each
LD block is illustrated with a black line around the circles.
First, we ranked all SNPs on the basis of the conjunction FDR
and removed SNPs in LD r2 > 0.2 with any higher ranked SNP
(Figure S8).Results
Q-Q Plots of SCZ SNPs Stratified by Association with
Pleiotropic CVD Risk Factors
Stratified Q-Q plots for SCZ conditioned on nominal
p values of association with TGs showed enrichment across
different levels of significance for TGs (Figure 1A). The
earlier departure from the null line (leftward shift) suggests
a greater proportion of true associations for a given
nominal SCZ p value. Successive leftward shifts for
decreasing nominal TG p values indicate that the propor-
tion of non-null effects varies considerably across
different levels of association with CVD risk factors. For
example, in the –log10(pTG) R 3 category, the proportion7, 2013
Table 1. Conditional FDR: SCZ Loci Given CVD Risk Factors
Locus SNP Gene Region MIM Chr SCZ p Value SCZ FDR
Minimum
Conditional FDR
CVD Risk
Factor
4 rs1625579 AK094607a 614304 1p21.3 5.52 3 106 0.02105 0.00420 TG
9 rs2272417 IFT172 607386 2p23.3 4.47 3 105 0.07516 0.00193 TG
17 rs17180327 CWC22 - 2q31.3 6.37 3 106 0.02332 0.00780 HDL
20 rs13025591 AGAP1 608651 2q37 9.26 3 106 0.02953 0.00131 TG
22 rs2239547 ITIH4a 600564 3p21.1 1.73 3 105 0.03920 0.00400 HDL
23 rs11715438 PTPRG 176886 3p21-p14 2.47 3 106 0.01601 0.00222 HDL
26 rs9838229 DKFZp434A128 - 3q27.2 1.11 3 105 0.02953 0.00825 HDL
37b rs2021722 TRIM26a 600830 6p21.3 2.08 3 109 0.00046 0.00001 TG
38 rs7383287 HLA-DOB 600629 6p21.3 3.44 3 105 0.06382 0.00748 HDL
39 rs1480380 HLA-DMA 142855 6p21.3 3.05 3 106 0.01746 0.00028 TG
40 rs9462875 CUL9 607489 6p21.1 1.20 3 105 0.03383 0.00739 WHR
42 rs1107592 MAD1L1 602686 7p22 7.63 3 107 0.00919 0.00493 HDL
48 rs10503253 CSMD1a 608397 8p23.2 3.96 3 106 0.01912 0.00432 TG
51 rs12234997 AK055863 - 8p23.1 2.23 3 105 0.04590 0.00347 TG
55 rs755223 BC037345 - 8q12.3 6.91 3 105 0.10338 0.00895 HDL
56 rs7004633 MMP16a 602262 8q21.3 2.60 3 107 0.00504 0.00141 HDL
65 rs11191580 NT5C2a 600417 10q24.32 3.73 3 107 0.00625 0.00013 SBP
rs7914558 CNNM2a 607803 10q24.32 1.90 3 106 0.01464 0.00101 HDL
rs2296569 CNNM2 607803 10q24.32 3.78 3 106 0.01912 0.00127 TG
rs10748835 AS3MT 611806 10q24.32 2.21 3 106 0.01464 0.00274 HDL
67 rs11191732 NEURL 603804 10q25.1 2.55 3 106 0.01601 0.00160 HDL
71 rs2172225 METT5D1 - 11p14.1 4.88 3 105 0.08828 0.00238 TG
rs7938219 CR618717 - 11p14.1 3.75 3 105 0.07516 0.00331 TG
78 rs548181 STT3A 601134 11q23.3 4.65 3 107 0.00707 0.00044 WHR
rs11220082 FEZ1 604825 11q24.2 2.84 3 106 0.01746 0.00279 TG
rs671789 PKNOX2 613066 11q24.2 1.46 3 105 0.03920 0.00695 WHR
80 rs7972947 CACNA1Ca 114205 12p13.2 7.12 3 106 0.02609 0.00415 TG
81 rs4765905 CACNA1Ca 114205 12p13.3 7.99 3 106 0.02609 0.00758 TG
84 rs8003074 KIAA0391 609947 14q13.2 7.23 3 106 0.02609 0.00484 HDL
rs10135277 KIAA0391 609947 14q13.1 5.02 3 106 0.02105 0.00491 TG
87 rs1869901 PLCB2 604114 15q15 3.66 3 106 0.01912 0.00203 TG
101 rs17597926 TCF4a 602272 18q21.1 6.49 3 107 0.00805 0.00216 TG
Independent complex or single-gene loci (r2 < 0.2) with SNP(s) with a conditional FDR < 0.01 in SCZ given the association in CVD risk factors. We defined the
most significant SCZ SNP in each LD block on the basis of the minimum conditional FDR for each phenotype. Listed are the most significant SNPs in each gene of
the LD block, as well as the CVD risk factor that provided the signal. All loci with SNPs with conditional FDR < 0.05 were used for defining the number of the loci
(Table S2). This and the respective FDR values in each phenotype are listed in Table S2. SCZ FDR values < 0.01 are in bold. The following abbreviations are used:
chr, chromosomal region; SCZ, schizophrenia; FDR, false-discovery rate; CVD, cardiovascular disease; TG, triglyceride; HDL, high-density lipoprotein; WHR, waist-
to-hip ratio; and SBP, systolic blood pressure.
aSame locus identified in previous SCZ GWASs. All data were first corrected for genomic inflation.
bThere are additional independent SNPs in the HLA region on chromosome 6 (locus 37). The complete SNP list is shown in Table S6.of SNPs reaching a given significance level (e.g.,
–log10(pSCZ) > 6) is roughly 100 times greater than that
for the –log10(pTG) R 0 category (all SNPs), indicating
a very high level of enrichment. Similarly, a clear pleio-The Americtropic enrichment was also seen for HDL and LDL choles-
terol. A less clear pleiotropic enrichment was seen forWHR
(Figure 1B), BMI, and SBP, but there was no evidence for
enrichment in T2D (data not shown).an Journal of Human Genetics 92, 197–209, February 7, 2013 203
Figure 2. Conditional Manhattan Plot
Conditional Manhattan plot of conditional –log10 (FDR) values for SCZ alone (black) and SCZ given the following CVD risk factors: TGs
(SCZjTG, red), LDL (SCZjLDL, orange), HDL (SCZjHDL, cyan), SBP (SCZjSBP, green), BMI (SCZjBMI, purple), WHR (SCZjWHR, blue),
and T2D (SCZjT2D, chartreuse). SNPs with conditional –log10 FDR > 1.3 (i.e., FDR < 0.05) are shown with large points. A black line
around the large points indicates the most significant SNP in each LD block, and this SNP was annotated with the closest gene, which
is listed above the symbols in each locus (except for the HLA region on chromosome 6) and in Table S2. The figure shows the local-
ization of 106 loci on a total of 21 chromosomes (1–19, 21, and 22). Details for the loci with –log10 FDR > 2 (i.e., FDR < 0.01) are shown
in Table 1.Conditional TDR in SCZ Is Increased by CVD Risk
Factors
Because categories of SNPs with stronger pleiotropic en-
richment are more likely to be associated with SCZ, all
tag SNPs should not be treated exchangeably so that
power for discovery can be maximized. Specifically, varia-
tion in enrichment across pleiotropic categories is ex-
pected to be associated with corresponding variation in
the TDR (equivalent to 1 – FDR)40 for association of SNPs
with SCZ. A conservative estimate of the TDR for each
nominal p value is equivalent to 1 – (p / q), easily obtained
from the stratified Q-Q plots. This relationship is shown
for SCZ conditioned on TG (Figure 1C) and WHR (Fig-
ure 1D). For a given conditional TDR, the corresponding
estimated nominal p value threshold varies by a factor of
100 from the most to the least enriched SNP category
(strata) for SCZ conditioned on TG (SCZjTG) and approxi-
mately by a factor of 40 for SCZ conditioned on WHR
(SCZjWHR). Phenotypes with weaker pleiotropy with
SCZ showed smaller increases in conditional TDR (data
not shown). Because TDR is strongly related to predicted
replication rate, it is expected that the replication rate
will increase for a given nominal p value for SNPs in cate-
gories with higher conditional TDR.204 The American Journal of Human Genetics 92, 197–209, FebruaryReplication Rate in SCZ Is Increased by Pleiotropic
CVD Risk Factors
To demonstrate that the observed pattern of differential
enrichment does not result from spurious (i.e., nongenera-
lizable) associations due to category-specific stratification
or errors in statistical modeling, we also studied the
empirical replication rate across independent substudies
of SCZ. Figures 1E and 1F show the empirical cumulative
replication-rate plots as a function of nominal p value
for the same categories as for the conditional stratified
TDR plots in Figures 1C and 1D. Consistent with the
conditional TDR pattern, we found that the nominal
p value corresponding to a wide range of replication rates
was 100 times higher for the –log10(pTG) R 3 category
than for the –log10(pTG) R 0 category (Figure 1E). Simi-
larly, SNPs from pleiotropic SNP categories showing the
greatest enrichments (–log10(pTG) R 3) replicated at the
highest rates—up to five times higher than all SNPs
(–log10(pTG)R 0)—for a wide range of p value thresholds.
This suggests that adjusting p value thresholds according
to the estimated category-specific conditional TDR could
improve the discovery of replicating SNP associations.
The same relationship between conditional TDR and repli-
cation rate was shown for SCZjWHR (Figure 1F), but here,7, 2013
Table 2. Conditional FDR: CVD-Risk-Factor Loci Given SCZ
Locus SNP Gene MIM Chr TGjSCZ LDLjSCZ HDLjSCZ SBPjSCZ BMIjSCZ WHRjSCZ T2DjSCZ
9 rs780110 IFT172 607386 2p23.3 0.00000 0.73578 0.66350 0.88851 0.57686 0.01079 1.00000
rs2272417 IFT172 607386 2p23.3 0.00000 0.86268 0.55896 0.83749 0.70039 0.06244 1.00000
20 rs6759206 AGAP1 608651 2q37 0.01764 0.89696 0.25333 1.00000 1.00000 0.95347 1.00000
22 rs3617 ITIH3 146650 3p21.1 0.69128 0.84071 0.37022 0.97795 0.45287 0.00942 1.00000
rs2276817 ITIH4 600564 3p21.1 0.28255 0.04717 0.25333 0.61208 0.45287 1.00000 1.00000
37 rs2328893 SLC17A4 604216 6p22.2 0.03788 0.34581 0.00396 0.83749 0.65586 1.00000 1.00000
rs1324082 SLC17A1 182308 6p22.2 0.03113 0.63999 0.00465 0.65717 0.78940 0.95347 1.00000
rs13198474 SLC17A3 611034 6p22.2 0.69128 0.73578 0.00289 0.80634 1.00000 0.93285 1.00000
rs16891235 HIST1H1A 142709 6p22.2 0.95191 0.02569 0.00213 0.70268 1.00000 0.93285 1.00000
rs13194781 HIST1H2BN 602801 6p22.2 0.00239 0.97314 0.14244 0.88851 1.00000 0.93285 1.00000
rs1235162 GABBR1 603540 6p22.1 0.00117 0.73578 0.10885 0.70268 0.82974 1.00000 1.00000
rs2844762 HLA-B 142830 6p22.1 0.00491 0.53895 0.78537 0.61208 NA 0.93285 1.00000
rs3130380 HCG18 - 6p22.1 0.00708 0.73578 0.01852 0.77857 0.70039 0.81643 1.00000
rs2524222 GNL1 143024 6p22.1 0.28255 0.02945 0.41447 0.80634 1.00000 0.93285 1.00000
rs9262143 KIAA1949 610990 6p22.1 0.00004 0.26238 0.05759 0.77857 0.92201 0.52829 1.00000
rs3095326 IER3 602996 6p22.1 0.00003 0.04717 0.04502 0.74450 0.92201 0.42354 1.00000
rs3099840 HCP5 604676 6p21.3 0.00000 0.39032 0.02988 0.28698 1.00000 0.37454 1.00000
rs2284178 HCP5 604676 6p21.3 0.01764 0.48709 0.25333 0.18351 0.74603 0.87368 1.00000
rs805294 LY6G6C 610435 6p21.33 1.00000 0.97314 0.12393 0.00248 0.61339 0.75370 1.00000
rs3117577 MSH5 603382 6p21.3 0.00000 0.02164 0.41447 0.61208 0.87106 0.42354 1.00000
rs3130679 C6orf48 605447 6p21.33 0.00000 0.07243 0.14244 0.41364 0.70039 0.13758 1.00000
rs412657 AK123889 - 6p21.33 0.69128 0.97314 0.03447 0.65717 0.65586 0.37454 1.00000
rs9268219 C6orf10 606766 6p21.33 0.00000 0.04220 0.12393 0.38400 0.65586 0.03366 1.00000
rs3129963 BTNL2 606000 6p21.33 0.59071 0.77938 0.00548 0.52604 0.92201 0.04119 1.00000
rs9268853 HLA-DRA 142860 6p21.3 0.69128 0.81421 0.03447 0.41364 0.61339 0.02983 1.00000
rs9275524 HLA-DQA2 613503 6p21.32 0.00409 0.03128 0.00548 0.33310 0.27214 0.05832 1.00000
39 rs1480380 HLA-DMA 142855 6p21.3 0.00708 0.86268 0.41447 0.18351 0.78940 0.10401 NA
40 rs7832 C6orf108 - 6p21.1 0.03399 0.97057 0.10762 NA NA NA NA
51 rs983309 AK055863 - 8p23.1 0.48760 0.00000 0.00000 0.80634 0.78940 0.47533 1.00000
rs17660635 AK055863 - 8p23.1 0.69128 0.00080 0.00010 0.74450 0.92201 0.81643 1.00000
65 rs4919666 SUFU 607035 10q24.32 0.85168 0.86268 0.78537 0.04405 0.40025 0.87368 1.00000
rs2296569 CNNM2 607803 10q24.32 0.15574 0.59079 0.03950 1.00000 1.00000 1.00000 1.00000
rs11191560 NT5C2 600417 10q24.32 0.69128 0.97314 0.72193 0.00000 0.02776 0.47533 1.00000
rs11191580 NT5C2 600417 10q24.32 0.78905 1.00000 0.61021 0.00000 0.02897 0.52829 1.00000
71 rs2958625 METT5D1 - 11p14.1 0.00491 0.89696 0.02569 0.88851 0.52128 0.52829 1.00000
rs10835491 METT5D1 - 11p14.1 0.00409 0.89696 0.03950 0.88851 0.52128 0.52829 1.00000
78 rs10790734 PKNOX2 613066 11q24.2 0.37774 0.89696 1.00000 0.80634 0.65586 0.04476 1.00000
For the independent complex or single-gene loci (r2 < 0.2) with SNP(s) with a conditional FDR < 0.01 in SCZ given associated CVD risk factors (Table 1), the
conditional FDR in the other direction is provided, i.e., FDR CVD risk factors given association in SCZ. All independent loci are listed consecutively, and the
same locus numbering is used as in Table 1. All data were first corrected for genomic inflation. FDR values < 0.05 are in bold. The following abbreviations are
used: chr, chromosomal region; TG, triglyceride; SCZ, schizophrenia; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure;
BMI, body mass index; WHR, waist-to-hip ratio; T2D, type 2 diabetes; and NA, not available.
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the increase in enrichment, and thus the increase in repli-
cation rate, was weaker than that for SCZjTG.
SCZ Gene Loci Identified with Conditional FDR
To identify SNPs associated with SCZ, we constructed
a conditional Manhattan plot showing the FDR condi-
tional on each of the CVD risk factors (Figure 2). We iden-
tified significant loci located on a total of 21 chromosomes
(1–19, 21, and 22) associated with SCZ, leveraging the
reduced FDR obtained by the associated CVD risk factor.
To estimate the number of independent loci, we pruned
the associated SNPs (i.e., removed SNPs with LD > 0.2)
and identified a total of 106 independent loci with a signif-
icance threshold of conditional FDR < 0.05 (Table S2).
With the more conservative conditional-FDR threshold
of 0.01, there remained 25 significant independent loci,
of which 4 were complex and 21 were single genes (Table 1
and black line around large circles in Figure 2). The largest
locus was on chromosome 6 in the human-leukocyte-
antigen (HLA) region. This is the only locus that would
have been discovered by standard methods based on
p values (Bonferroni correction), and the 6p21.3 region
(close to TRIM26 [MIM 600830]) was significantly associ-
ated with SCZ in the primary analysis of the current
sample.13 With the FDR method in SCZ alone, six loci
were identified. Of these, the regions close to TRIM26
(6p21.3), MMP16 (8q21.3 [MIM 602262]), CNNM2/
NT5C2 (10q24.32 [MIM 607803 and 600417]), and TCF4
(18q21.1 [MIM 602272]) were identified in earlier GWASs
only after large replication samples were included,13,15
except for 6p21.3. The remaining 19 loci would not
have been identified in the current sample without the
use of the pleiotropy-informed stratified FDR method.
Of interest, the AK094607/MIR137 region (1p21.3 [MIM
614304]) and the CSMD1 region (8p23.2 [MIM 608397])
were identified in the primary analysis of the current SCZ
sample after the inclusion of a large replication sample,13
and the ITIH4 (3p21.1 [MIM 600564]) and CACNA1C
(12p13.3, locus 81 [MIM 114205]) regions were identified
in the primary analysis after combination with a large
bipolar-disorder sample.12,13 Thus, the current pleiot-
ropy-informed FDR method validated nine loci discovered
in considerably larger samples and discovered 16 addi-
tional loci. Furthermore, several of these additional loci
are located in regions with borderline significance associa-
tion with SCZ in previous studies: AGAP1 (2q37; CENTG2
[MIM 608651]),13 PTPRG (3p21 [MIM 176886]),13
MAD1L1 (7p22 [MIM 602686]),43 STT3A (11q23.3 [MIM
601134]),13 and PLCB2 (15q15 [MIM 604114]).13
Pleiotropic Gene Loci in SCZ and CVD Risk Factors
Identified with Conjunction FDR
As a secondary analysis, we investigated whether any
of the SNPs associated with SCZ conditioned on CVD
(SCZjCVD) were also significantly associated with CVD
risk factors conditioned on SCZ (CVDjSCZ), i.e., the condi-
tional FDR in the opposite direction. We identified ten206 The American Journal of Human Genetics 92, 197–209, Februaryindependent loci (pruned on the basis of LD > 0.2) with
a significant association also with the CVD risk factor
(conditional FDR < 0.05); these included three complex
loci and seven single-gene loci (Table 2). Of these, the
ITIH4 region (3p21.1) and the CNNM2/NT5C2 region
(10q24.32), in addition to the HLA region on chromosome
6, have been identified in previous SCZ studies after the
inclusion of large replication samples.13 The significant
loci were found in the analyses of TGjSCZ (six loci),
LDLjSCZ (three loci), HDLjSCZ (four loci), SBPjSCZ (two
loci), BMIjSCZ (one locus), and WHRjSCZ (four loci), and
six loci were jointly associated with SCZ and more than
one CVD risk factor (Table 2). This suggests that overlap-
ping genetic pathways are involved in SCZ and CVD risk
factors. The direction of the different SNP associations
(Z scores) is shown in Table S3. There was no clear evidence
for systematic directions across any of the SNPs in the
different phenotypes, probably as a result of complex LD
structures, especially on chromosome 6.
Further, to provide a comprehensive, unselected map of
pleiotropic loci between SCZ and CVD risk factors, in addi-
tion to those primarily associated with SCZ, we performed
a conjunction-FDR analysis and constructed a conjunction
Manhattan plot (Figure S8). We detected 26 independent
pleiotropic loci (pruned on the basis of LD > 0.2; black
line around large circles) with a significance threshold of
conjunction FDR < 0.05 on a total of 14 chromosomes.
See Table S4 for more details.Discussion
Here, leveraging the power of GWAS data from over
250,000 individuals, we demonstrate that GWASs from
associated CVD risk factors can improve discovery of SCZ
susceptibility loci. By using the stratified conditional-FDR
approach34,35 in the combined analyses of the SCZ and
CVD-risk-factor GWASs, we identified a total of 25 signifi-
cant loci. By analyzing the SCZ GWAS alone, we identified
five loci. In contrast, with standard GWAS methods, one
locus was significant in the SCZ sample after genomic-
control correction.13 The identified pleiotropic loci are
associated with overlapping biological processes, and
nine of them have been identified in previous SCZ GWASs
after the inclusion of large additional samples. This shows
the feasibility of using a pleiotropy-informed stratified FDR
approach in SCZ in combination with associated pheno-
types; it is much more cost efficient than increasing the
sample size of SCZ individuals.44
To date, it has been difficult to use GWASs to discover
a significant proportion of the missing heritability of com-
plex human traits and disorders. Our statistical frame-
work is based on the fact that SNPs are not exchangeable.
Rather, SNPs with effects in pleiotropic phenotypes have
a higher probability of being true non-nulls and hence
also a higher probability of being replicated in indepen-
dent studies. We therefore developed a conditional-FDR7, 2013
approach for GWAS summary statistics by adapting strati-
fication methods originally used for linkage analysis and
microarray expression data.34,35 Decreased conditional
FDR (equivalently, increased conditional TDR) for a given
nominal p value increases power to detect true non-null
effects. Increased conditional TDR is directly related to
increased replication effect sizes and replication rates in
de novo samples. Importantly, we validated the condi-
tional-FDR approach by demonstrating increased replica-
tion rates in independent SCZ substudies for given
nominal p value cutoffs. Equivalently, conditional FDR
can be used for controlling FDR at a given level while
increasing power to discover non-null SNPs over the
usual unconditional approaches that treat all SNPs as
exchangeable.45
We also developed a conjunction-FDR approach to
identify SNPs that are highly pleiotropic with SCZ and
one or more CVD risk factors. The conjunction FDR is
the minimum of the conditional FDR for SCZ given
a CVD risk factor and vice versa. SNPs that exceed a strin-
gent conjunction-FDR threshold are highly probable to
be non-null in two phenotypes simultaneously. Of note,
conjunction FDR is different from the Fisher combined
probability test, for which the alternative hypothesis is
that the SNP has a significant effect on at least one (but not
necessarily both) phenotypes. We validated our approach
by applying a bivariate model to estimate the covariation
between SCZ and the CVD risk factors. This showed that
for the pleiotropic phenotypes, the degree of pleiotropy
is highly significantly different from zero (Figure S3).
Further confidence in the significance of the current
findings comes from the CI Q-Q plots (Figure S2), which
show significant pleiotropic enrichment. Given that the
current analyses are based on GWAS summary statistics,
the findings depend on correctly computed p values in
the original studies.
The current findings of difference in magnitude of
enrichment and variation in the pleiotropic loci across
the three lipid phenotypes show that the results are not
driven by genetic stratification, given that the lipid
phenotypes were all obtained from the same individ-
uals30 and each had approximately the same sample size.
Moreover, the improved replication rate with increasing
pleiotropic enrichment further argues against nonspecific
genetic stratification. As such, polygenic pleiotropy could
potentially be a nonspecific phenomenon related to heri-
table human phenotypes, but the lack of polygenic
enrichment and of significant loci between SCZ and T2D
(an example of a successful GWAS31) suggests that the
current results are phenotype specific. It is unlikely that
nongenetic correlations explain the observed pleiotropy
given that only a fraction of control participants in the
CVD-risk-factor GWAS samples overlapped with the SCZ
GWAS samples (WTCCC controls). The replication rate
based on substudies was not driven by the UK sample
(which included the overlapping WTCCC controls), as
shown in Figure S4. The current threshold for significantThe Americassociation of SCZjCVD was set at FDR < 0.01 as a result
of the seven CVD risk factors tested. However, the CVD
risk factors are highly correlated, and thus the 0.01 level
is conservative despite the number of CVD phenotypes
tested and is comparable to the standard FDR threshold
of 0.05, which translates to 5 false positives per 100
findings.
In the current study, we defined pleiotropy as the associ-
ation between a single gene or variant and more than one
distinct phenotype (diseases or traits).9 It is possible that
some of the loci identified in the current study might not
be pleiotropic but rather underlie common aspects of the
SCZ and CVD-risk-factor phenotypes.9 This can be investi-
gated in samples with more detailed phenotypes. In the
present study, we focused on SNPs, but gene-based pleiot-
ropy is also interesting;8 however, this requires raw data
from individual participants.
Our results implicate potential shared pathological
mechanisms between SCZ and CVD risk factors. The ten
pleiotropic loci were associated with multiple CVD pheno-
types, supporting the hypothesis that the pathobiology
of SCZ is heterogeneous and has numerous underlying
mechanisms. The majority of the pleiotropic signal was
found with lipid levels, suggesting that lipid biology
might be involved in SCZ pathophysiology. As such, genet-
ically determined dyslipidemia in SCZ is in line with
evidence for white-matter abnormalities and myelin
dysfunction46,47 and supports the neurodevelopmental
hypothesis.48 However, the lack of consistent direction-
ality suggests the need for further experimental studies
for determining the mechanistic relationship between dys-
lipidemia and SCZ.
Our results show that a ‘‘model-free,’’ empirical, FDR
framework that uses unthresholded summary-statistics
data from independent GWASs can provide insights into
relationships between risk factors and diseases. This
approach can be used for examining the shared genetic
basis between a number of diseases and traits. With the
recent discovery of many common genetic variants influ-
encing diseases and traits, there is increasing interest in
pleiotropy. One recent review suggests that pleiotropy is
common and associated with ~17% of genes and ~5%
of SNPs associated with complex humans diseases and
traits.9 In addition to identifying potential targets for
drug development, gaining insight into the degree of
genetic ‘‘connectivity’’ between diseases and traits pro-
vides an opportunity to ascertain whether current diag-
noses and classifications are consistent with genetic
architecture or whether genetic similarities traverse clinical
conditions. Examining overlap in common variants can
elucidate important pathobiology and might identify
potential therapeutic targets for common diseases.
In conclusion, the current findings demonstrate that in
SCZ, the pleiotropy-informed stratified FDR method can
improve the statistical power for detecting ‘‘polygenic’’
effects and can offer insights into mechanistic relation-
ships between lipid biology and SCZ pathogenesis.an Journal of Human Genetics 92, 197–209, February 7, 2013 207
Supplemental Data
Supplemental Data include eight figures, six tables, and a list of
Schizophrenia Psychiatric GWAS Consortium members and can
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